Evaluation of Antiurolithiatic Activity of Asparagus Racemosus on In Vitro Calcium Oxalate Crystallization Methods

Pharmaceutical Science-Pharmacology For Drug Discovery

Abstract

The primary purpose of this research was to interrogate the antiurolithiatic impact of the aqueous root extract of Asparagus  racemosus  (AEAR)  on  in  vitro  crystallization  methodology.  AEAR  is  generally  known  as  Shatavari,  belongs  to Asparagaceae family and it consists of various phytochemical components, such as alkaloids, amino acids, proteins, steroids, saponins, flavonoids, tannins, phenols and carbohydrates. The antiurolithiatic activity was studied in the availability and lack of AEAR at the concentration range of 100-1000 µg/ml by accessing crystal nucleation, crystal aggregation, and crystal growth assay methods.  Standard  drug  Cystone  was  made  use  of  positive  control  in  the  concentration  range  of  100-1000  µg/ml.  The percentage inhibition frequency of crystal nucleation, crystal aggregation and crystal growth by AEAR and standard drug cystone was recognized to be dose-dependent in nature. The percentage inhibition of crystal nucleation, crystal aggregation, and crystal growth of cystone and AEAR was found to be 82.31±7.26 % and 65.62±5.66 %, 67.90±3.47 % and 59.54±2.13 %, 72.04±4.46 % and 59.15±4.12 %, respectively. The half maximal inhibitory concentration (IC50) estimates of the standard drug cystone on crystal nucleation, crystal aggregation and crystal growth were computed to be 415.30±21.35, 573.7±65.53 and 566.20±62.06 µg/ml, respectively, while the AEAR, IC50   values were reported to be 689.60±17.16, 818.10±60.56 and 760.30±71.07 µg/ml, respectively. The current results of the in vitro crystallization analysis demonstrated that an aqueous root extract of Asparagus racemosus presents calcium oxalate crystal inhibition potential on crystal nucleation, crystal aggregation, and crystal growth specified as a significant and promising antiurolithiatic function.